Loading…
For most adults with elevated ApoB and any additional risk factor: yes. The risk-benefit case is well-studied.
Statins lower ApoB which lowers cardiovascular events — among the most-replicated findings in medicine.
Our read is Well Supported. The intervention clears a strong evidence base (88/100) with broad agreement among the voices we track (84% consensus). At $15/month and low effort, taking a statin for primary prevention is one of the more defensible moves on this list — the burden of proof has largely been met.
Pulled the public claims about taking a statin for primary prevention from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Talk to your doctor. This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so taking a statin for primary prevention is not a casual decision. Loop in a clinician who can see your full history before starting.
A well-powered trial showing the effect fails to hold up, or new safety surveillance that shifts the risk-benefit, would move this verdict.
Mechanistic and trial evidence converge on a real, replicable effect.
The effect size is large enough to matter clinically, not just statistically.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
The headline effect shrinks once you account for trial quality.